The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 47 | — | 20.1x | Near average | |
Growth | 85 | 150.3% | 5.6% | Above average | |
Quality | 85 | 27.3% | 7.6% | Above average | |
Safety | 42 | -0.8x | 0.4x | Near average | |
Capital Return | 32 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Phathom Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Phathom Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
PHAT stock shows remarkable stability in analyst estimates over the past 30 days, with the average price target steadying at 24.67 dollars, representing a significant price premium exceeding 100% over the current price (11.33 dollars). The consistency of the consensus among 5 analysts reflects a state of anticipation for new operational catalysts, with a Dispersion between the low of 18 dollars and the high of 28 dollars, indicating a general agreement on the current undervaluation of the stock despite operational risks.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.